Malta - enska - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - cytarabine - solution for injection - cytarabine 100 mg/ml - antineoplastic agents

Malta - enska - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - cytarabine - solution for injection/infusion - cytarabine 20 mg/ml - antineoplastic agents

Malta - enska - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - cytarabine - solution for injection/infusion - cytarabine 20 mg/ml - antineoplastic agents

Írland - enska - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - nevirapine anhydrous - tablet - 200 milligram(s) - non-nucleoside reverse transcriptase inhibitors; nevirapine

Malta - enska - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - nevirapine - tablet - nevirapine 200 mg - antivirals for systemic use

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - nevirapine -

Malta - enska - Medicines Authority

sandoz pharmaceuticals d.d. verovškova ulica 57, si-1000 ljubljana, slovenia - nevirapine - tablet - nevirapine 200 mg - antivirals for systemic use

Bandaríkin - enska - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - nelarabine (unii: 60158cv180) (nelarabine - unii:60158cv180) - nelarabine injection is indicated for the treatment of t-cell acute lymphoblastic leukemia (t-all) and t-cell lymphoblastic lymphoma (t-lbl) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. none. risk summary based on its mechanism of action and findings in animal studies, nelarabine can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . limited available data with nelarabine use in pregnant women are insufficient to determine a drug-associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes. there are risks to the pregnant woman associated with untreated leukemia or lymphoma (see clinical considerations). in animal reproduction studies, intravenous administration of nelarabine to pregnant rabbits during the period of organogenesis resulted in teratogenicity at maternal doses below the recommended human adult dose of 1,500

Bandaríkin - enska - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - nelarabine (unii: 60158cv180) (nelarabine - unii:60158cv180) - nelarabine injection is indicated for the treatment of t-cell acute lymphoblastic leukemia (t-all) and t-cell lymphoblastic lymphoma (t-lbl) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. none. risk summary based on its mechanism of action and findings in animal studies, nelarabine can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . limited available data with nelarabine use in pregnant women are insufficient to determine a drug-associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes. there are risks to the pregnant woman associated with untreated leukemia or lymphoma (see clinical considerations). in animal reproduction studies, intravenous administration of nelarabine to pregnant rabbits during the period of organogenesis resulted in teratogenicity at maternal doses below the recommended human adult dose of 1,500

Bandaríkin - enska - NLM (National Library of Medicine)

dr. reddy's laboratories, inc. - nelarabine (unii: 60158cv180) (nelarabine - unii:60158cv180) - nelarabine injection is indicated for the treatment of t-cell acute lymphoblastic leukemia (t-all) and t-cell lymphoblastic lymphoma (t-lbl) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. none. risk summary   based on its mechanism of action and findings in animal studies, nelarabine can cause fetal harm when administered to a pregnant woman [ see clinical pharmacology ( 12.1) ]. limited available data with nelarabine use in pregnant women are insufficient to determine a drug-associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes. there are risks to the pregnant woman associated with untreated leukemia or lymphoma (see clinical considerations ). in animal reproduction studies, intravenous administration of nelarabine to pregnant rabbits during the period of organogenesis resulted in teratogenicity at maternal doses below the recommended human adult dose of